Drug Profile
Toludesvenlafaxine extended release - Luye Pharma
Alternative Names: 4-Methylbenzoate desvenlafaxine hydrochloride; Anshufaxine hydrochloride extended release - Luye pharma; Ansofaxine hydrochloride extended release - Luye Pharma; Desvenlafaxine prodrug; LPM-570065; LY-03005; Ruoxinlin; Toludesvenlafaxine hydrochloride extended release - Luye PharmaLatest Information Update: 07 Sep 2023
Price :
$50
*
At a glance
- Originator Luye Pharma Group
- Class Antidepressants; Anxiolytics; Benzoates; Cyclohexanols; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Major depressive disorder
- Phase III Generalised anxiety disorder
Most Recent Events
- 07 Sep 2023 Phase-II clinical trials in Major depressive disorder in Japan prior to September 2023 (PO) (Luye Pharma pipeline, September 2023)
- 12 Jul 2023 Luye Pharma Group initiates phase III clinical trial in Generalised anxiety disorder in China (PO) (NCT05970510)
- 28 Apr 2023 No recent reports of development identified for clinical-Phase-Unknown development in Major depressive disorder in Europe (PO, Controlled release)